Lenacapavir (Yeztugo, Gilead) should be one choice available for people to take as pre-exposure prophylaxis (PrEP) for HIV, according to new guidelines released by WHO during IAS 2025, in Kigali, Rwanda.
Twice-yearly lenacapavir, which was just approved by the FDA in June, should be considered a PrEP option along with other WHO-recommended treatments: daily oral PrEP, injectable cabotegravir (Apretude, ViiV Healthcare) and the dapivirine vaginal ring. (The dapivirine vaginal